In the same way, expression of CCL4 in U87i and U87w cells were strongly increased in the BBB models with PBMCs from control patients (by 29.92-fold, and 52.33-fold for U87i and U87w cells respectively), and from mild AD patients (by 27.65-fold, and 42.89-fold for U87i and U87w cells respectively) and from moderate patients (by 23.31-fold and 34.20 fold for U87i and U87w cells respectively) versus BBB models without PBMCs (Table 3). This evidence concerns the gene CCL4 and Alzheimer disease.